Guillem Loren

Guillem Loren

Auto-generated profile, based on publicly available information

Guillem Loren

MiMARK Diagnostics SL, Parc Científic de Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
GLGuillem Loren
Guillem Loren
IEIrene Espuny
Irene Espuny
ALAlicia Llorente
Alicia Llorente
CDCraig Donoghue
Craig Donoghue
XVXavier Verdaguer
Xavier Verdaguer
ARAntoni Riera
Antoni Riera
In the last four decades, treatment of oestrogen receptor positive (ER+) breast cancer (BCa), has focused on targeting the estrogenic receptor signaling pathway. This signaling function is pivotal to sustain cell proliferation. Tamoxifen, a competitive inhibitor of oestrogen, has played a major role in therapeutics. However, primary and acquired resistance to hormone blockade occurs in a large subset of these cancers, and new approaches are urgently needed. Aromatase inhibitors and receptor degraders were approved and alternatively used. Yet, resistance appears in the metastatic setting. Here we report the design and synthesis of a series of proteolysis targeting chimeras (PROTACs) that induce the degradation of estrogen receptor alpha in breast cancer MCF-7 (ER+) cells at nanomolar concentration. Using a warhead based on 4-hydroxytamoxifen, bifunctional degraders recruiting either cereblon or the Von Hippel Lindau E3 ligases were synthesized. Our efforts resulted in the discovery of TVHL-1, a potent ERα degrader (DC50: 4.5 nM) that we envisage as a useful tool for biological study and a platform for potential therapeutics.

18 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MCMónica Cubillos-Rojas
Mónica Cubillos-Rojas
GLGuillem Loren
Guillem Loren
YHYusuf Zaim Hakim
Yusuf Zaim Hakim
XVXavier Verdaguer
Xavier Verdaguer
ARAntoni Riera
Antoni Riera
Angel R. NebredaAngel R. Nebreda
Angel R. Nebreda
We report a series of small molecule proteolysis-targeting chimeras (PROTACs) that target the protein kinase p38α for degradation. These PROTACs are based on a ligand of the VHL E3 ubiquitin ligase, which is linked to an ATP competitive inhibitor of p38α. We provide evidence that these compounds can induce the specific degradation of p38α, but not p38β and other related kinases, at nanomolar concentrations in several mammalian cell lines. We also show that the p38α-specific PROTACs are soluble in aqueous solutions and therefore suitable for their administration to mice. Systemic administration of the PROTACs induces p38α degradation only in the liver, probably due to the PROTAC becoming inactivated in that organ, but upon local administration the PROTACs induce p38α degradation in mammary tumors. Our compounds provide an alternative to traditional chemical inhibitors for targeting p38α signaling in cultured cells and in vivo.

12 February 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
ALAna Luzarraga
Ana Luzarraga
RCRoger Canton
Roger Canton
GLGuillem Loren
Guillem Loren
JCJavier Carvajal
Javier Carvajal
ICIrene de la Calle
Irene de la Calle
Antonio Gil-MorenoAntonio Gil-Moreno
Antonio Gil-Moreno